155 results about "Deoxyglucose" patented technology

The invention relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin thereby treating or prevention various diseases, disorders or conditions. Additionally, the invention relates to treatment of various diseases, disorders or conditions associated with or mediated by oxidative stress since 3DG induces ROS and AGEs, which are associated with the inflammatory response caused by oxidative stress.

Methods are provided for cancer and pre-cancer detection by increased uptake of fluorophore glucose or deoxyglucose conjugates in cancerous and pre-cancerous cells relative to normal cells.

Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a fatty acid metabolism inhibitor, a glycolytic inhibitor, and / or an agent able to alter cellular production of reactive oxygen, or combination thereof, optionally in combination with one or more chemotherpeutic agents. In preferred embodiments, the invention combines an oxirane carboxylic acid, represented by etomoxir, with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose, and / or an antibody against UCP and / or Fas antigen. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers.

Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a UCP and / or Fas antibody or other inhibitor, or combination thereof, and a therapeutically acceptable amount of a fatty acid metabolism inhibitor and / or a therapeutically acceptable amount of a glucose metabolism inhibitor, optionally in combination with one or more chemotherpeutic agents. In preferred embodiments, the invention combines an antibody against UCP and / or Fas antigen with an oxirane carboxylic acid, represented by etomoxir, and / or with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers.

The present invention generally relates to systems and methods for treating inflammatory and proliferative diseases, and wounds, using a combination of (1) fatty acid metabolism inhibitors and (2) glycolytic inhibitors and / or UCP and / or Fas inhibitors or antibodies. More particularly, the invention combines an oxirane carboxylic acid compound, represented by etomoxir, with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose, and / or an antibody against UCP and / or Fas antigen. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers (i.e., cancers resistant to conventional cancer drug therapies).

Glycolytic inhibitors are useful in the treatment of solid tumors by attacking anaerobic cells at the center on the tumor. 2-deoxyglucose, oxamate and various analogs thereof are identified as having a natural selective toxicity toward anaerobic cells, and will significantly increase the efficacy of standard cancer chemotherapeutic and radiation regiments as well as new protocols emerging with anti-angiogenic agents.

The present disclosure provides compositions comprising 2-deoxyglucose-functionalized magnetic nanoparticles. The compositions are useful in various applications, which are also provided.

Glycolytic inhibitors are useful in the treatment of solid tumors by attacking anaerobic cells at the center on the tumor. 2-deoxyglucose, oxamate and various analogs thereof are identified as having a natural selective toxicity toward anaerobic cells, and will significantly increase the efficacy of standard cancer chemotherapeutic and radiation regiments as well as new protocols emerging with anti-angiogenic agents.

The invention provides a phenyl C-glucoside derivative (compound as shown in a formula I) containing a deoxyglucose structure and a preparation method thereof, a pharmaceutical composition including the same and application of the phenyl C-glucoside derivative containing a deoxyglucose structure in preparation of medicines for treating diabetes mellitus. The definitions of the substituent groups R1-R7 are as shown in the specification, and the formula I is as shown in the specification.

A tobacco foliar fertilizer and a preparation method thereof. The tobacco foliar fertilizer includes following components, by weight: 20-25 parts of potassium tripolyphosphate, 15-20 parts of potassium citrate, 3-6 parts of sargassum fermentation extract, 0.5-2 parts of glutathione, 0.5-2 parts of [beta]-deoxyglucose, 0.1-1 part of trans-abscisic acid, 0.5-1 part of xylooligosaccharide, 0.2-0.5 parts of salicylic acid, 1-3 parts of boric acid, 0.1-0.5 parts of ammonium molybdenate, 0.5-2 parts of EDTA-chelating zinc, 0.5-2 parts of EDTA-chelating magnesium, 0.3-2 parts of EDTA-chelating manganese, 0.3-1 part of EDTA-chelating copper, 0.5-1 part of alkyl polysaccharide glycoside and 31-56.2 parts of water. The tobacco foliar fertilizer is reasonable in combination and proportion, can promote growth of tobacco, can enhance the resistance capability on viruses, cold and dryness of tobacco, can increase yield, is green and environmental-friendly and can greatly improve quality of tobacco.

Bacterial polynucleotides and polypeptides are provided in which the polypeptides have a dehydrogenase activity, such as an alcohol dehydrogenase (ADH) activity, an uronate, a 4-deoxy-L-erythro-5-hexoseulose uronate (DEHU) ((4S,5S)-4,5 dihydroxy-2,6-dioxohexanoate) hydrogenase activity, a 2-keto-3-deoxy-D-gluconate dehydrogenase activity, a D-mannuronate hydrogenase activity, and / or a D-mannnonate dehydrogenase activity. Methods, enzymes, recombinant microorganism, and microbial systems are also provided for converting polysaccharides, such as those derived from biomass, into suitable monosaccharides or oligosaccharides, as well as for converting suitable monosaccharides or oligosaccharides into commodity chemicals, such as biofuels. Commodity chemicals produced by the methods described herein are also provided.

The invention relates to a beta-glucosidase and an application thereof, wherein the beta-glucosidase comprises: a, enzyme with the sequence of SEQ ID NO:1; and b, enzyme which is derived from the enzyme in step a through substituting, deleting or adding one or a plurality of amino acids and has the activity of the enzyme in the step a. The selected beta-glucosidase provided by the invention has the deoxyglucose and hygromycin resistance and transglycosylation, under the transglycosylation, cellobiose and other oligosaccharides can generate sophorose and other inductors, and enter cells through a constitution permease system on a cell membrane, and the synthesis of cellulose in the cells is initiated. Consequently, the beta-glucosidase can be used for the production of catalytically synthesizing the sophorose to induce the cellulose, and thereby having a greater commercial value.

The invention discloses a composition for controlling porcine respiratory disease complex and an application thereof. The composition comprises the following components: an echinacea purpurea herb extract product, nano-zinc oxide, Mycobacterium phlei, farrerol, deoxyglucose and astragalus polysaccharide. The composition is used as a feed additive to be applied for controlling porcine respiratory disease complex. By the adoption of the composition provided by the invention, the vast majority of disease causes which trigger porcine respiratory disease complex can be effectively inhibited and killed, various clinical symptoms can be controlled, course of the disease is shortened, death and culling rate is minimized, and growth speed of pigs is raised.

The present invention provides methods of method of synthesizing 2,5-furan dicarboxylic acid (FDCA) and FDCA precursor molecules. The methods involve performing a chemical dehydration reaction on a gluconic acid derivative in the presence of a dehydration catalyst. In some embodiments the gluconic acid derivative can be 2-dehydro-3-deoxy gluconic acid (DHG) or an ester thereof, 2-ketogluconic acid (2KGA) or an ester thereof, and 5-ketogluconic acid (5KGA) or an ester thereof. The 2,5-furan dicarboxylic acid precursor molecule is thereby synthesized, which can be converted into FDCA. The chemical dehydration can be performed by a variety of acid basic catalysts.

The present invention relates to novel antineoplastic agents and cancer diagnostic agents that specifically target neo-plastic cells via the GLUT transportation system. More specifically, the invention relates to conjugates of 2-deoxyglucose, wherein a linker, which includes a covalent bond, is attached to 2-deoxyglucose at the 2 position, and the linker is attached to a therapeutic or diagnostic agent. The invention also relates to methods of treating tumor disease and methods of making the novel compounds of the present invention. The agents of the present invention are superior to previous agents as they are targeted via GLUT transporters.

The present disclosure provides compositions comprising 2-deoxyglucose-functionalized magnetic nanoparticles. The compositions are useful in various applications, which are also provided.

A target substance can be produced by culturing a bacterium having an ability to produce 2-ketoglutaric acid or a derivative thereof, and an ability to produce xylonic acid from xylose, which is imparted with xylonate dehydratase activity, 2-keto-3-deoxyxylonate dehydratase activity and 2-ketoglutaric semialdehyde dehydrogenase activity, or in which these activities are enhanced, in a medium containing xylose as a carbon source to produce and accumulate the target substance in the medium, and collecting the target substance from the medium.

The invention discloses a method for preparing for 2-deoxyglucose. The method uses D-acetylated dextroglucose and the absolute methanol to obtain the D-gluglucosan on the accelerating effect, and then it dose vacuum distillation to evaporate to dryness the methanol, it adds sulfuric acid water solution on the reacting machine to obtain the 2-deoxyglucose by hydrolyzing, it then uses normal method to do re-crystallization to the course product to obtain the 2-deoxyglucose product.

The present invention relates to compositions and methods for treating cancer, by administering a combination comprising a jasmonate derivative (e.g., methyl jasmonate or a compound of any of formulae I through VII or any of the jasmonate derivatives exemplified by such formulae) and at least one other agent selected from a chemotherapeutic agent (e.g., a nitroso-urea, a platinum compound, a taxane derivative, an antitumor antibiotic) and an inhibitor of glycolysis (e.g., 2-deoxy-D-glucose). The jasmonate derivative and the at least one other agent together provide a therapeutic effect, which is preferably synergistic (cooperative).

The invention relates to the discovery that 3-deoxyglucosone (3DG) and other alpha-dicarbonyl sugars associated diseases and disorders are present and produced in the skin. Further, the invention relates to the discovery that amadorase, an enzyme that mediates 3DG synthesis, is also present in the skin. Thus, the invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin thereby treating or prevention various diseases, disorders or conditions. Additionally, the invention relates to treatment of various diseases, disorders or conditions associated with or mediated by oxidative stress since 3DG induces ROS and AGEs, which are associated with the inflammatory response caused by oxidative stress.

The present disclosure provides compositions comprising 2-deoxyglucose-functionalized magnetic nanoparticles. The compositions are useful in various applications, which are also provided.

Compound 2-deoxyglucose can be used to treat cancer, and when administered in therapeutically effective doses, and optionally co-administered with other anticancer drugs, or in combination with surgical resection or radiation therapy, can improve the treatment of patients Effect.

The invention relates to a method for improving one or more physical / chemical characteristics, like reduced radiolysis of and the ability to autoclave, a <18>F-fluor-deoxy-glucose (<18>F-FDG)-solution, which method comprises the steps of a) provision of a <18>F-fluor-deoxy-glucose (<18>F-FDG)-solution, and b) addition of at least one buffer based on a weak acid to the <18>F-fluor-deoxy-glucose (<18>F-FDG)-solution. The invention also relates to a method for preparing a sterile <18>F-fluor-deoxy-glucose (<18>F-FDG)-solution by autoclaving said <18>F-fluor-deoxy-glucose (FDG)-solution.

The invention provides an L-lactic acid catalysis reaction system and a preparation method of L-lactic acid. The L-lactic acid catalysis reaction system contains glucose dehydrogenase, dihydroxyacid anhydrase, 2-keto-3-deoxygluconate, glyceraldehyde phosphate dehydrogenase and L-lactic dehydrogenase. The L-lactic acid can be obtained without adding ATP (Adenosine Triphosphate) by performing a cascade enzymatic catalytic reaction in a reactor by utilizing five enzymes of the reaction system and taking glucose as a raw material.

The invention provides a 2-fluoro-aniline quinazoline compound labelled by F-18, wherein <18>F is produced by a circular accelerator via <18>O(pn)<18>F nuclear reaction and automatically synthesised by a radioactive synthesis module, and can also be produced by the existing domestic F-18 multifunctional synthesis device after process reformation. The 2-fluoro-aniline quinazoline compound provided by the invention is of an aniline quinazoline structure substituted by 2-bit positron nuclide fluorine-18, and can be modified on 6-bit, 7-bit and benzene ring connected with an amino group. The invention provides novel tumour positron imaging agents, wherein compared with <18>F-fluoro-deoxyglucose (<18>FDG), the imaging agents are specific, and capable of identifying the tumours highly expressed by an epidermal growth factor receptor (EGFR). The preparation method is reasonable in design, simple in labelling method, capable of realizing automatic production, and suitable for application. The structural general formula of the 2-fluoro-aniline quinazoline compound is defined in the specification.